News Hub | News Direct

Elsevier gives free access to content and resources via just-launched Monkeypox Information Center to accelerate fight against viral disease

Elsevier

For the benefit of healthcare professionals, medical researchers, and the public, Elsevier, a leading scientific publisher and global information analytics business specializing in science and health, has today launched a Monkeypox Information Center. The hub will be continually updated and provide free access to relevant research and clinical information on the Monkeypox virus from across Elsevier’s scientific and medical journals and clinical resources for healthcare professionals. This research and health information will be freely available from Elsevier platforms and shared with the World Health Organization (WHO). In addition, the company, will contribute Monkeypox-relevant journal articles to PubMed Central, the archive of biomedical and life sciences research at the U.S. National Institutes of Health’s National Library of Medicine, for as long as the Monkeypox public health emergency is ongoing. Updated frequently, The Monkeypox Information Center will offer access to journal articles and book chapters to ensure researchers, clinicians and the public can readily discover relevant content from the rapidly growing body of literature. It will also provide a machine-readable corpus to enable use of text and data mining technologies to identify patterns and relationships in data, as countries around the world address this global public health crisis. The Monkeypox Information Center is updated continuously with the latest research information on the virus and the disease. In addition, Monkeypox-related journal articles and book chapters are made freely available on ScienceDirect, Elsevier’s global platform of peer-reviewed scholarly literature. Around 400 journal articles were identified initially, and latest research and guidance will be added as they become available. The launch of this information center is part of Elsevier’s commitment to support the research and healthcare communities in their efforts to address public health emergencies and follows the company’s information hubs for Ebola, SARS, Zika and MERS outbreaks, and the current pandemic response continues to be supported by the existing novel coronavirus resource centre. “The Monkeypox Information Center will support healthcare professionals, clinical researchers, and policy makers in understanding Monkeypox, so that best efforts can be made towards its prevention and treatment,” said Kumsal Bayazit, CEO, Elsevier. “To support research and healthcare communities we serve, with the public health emergency, we are providing an information center where the medical community, patients, and their caregivers can readily access the most up-to-date information.” The Monkeypox Information Center is hosted on Elsevier Connect, the company’s public news and information website. It allows free access to content curated in consultation with Elsevier clinicians and other experts. It brings together content from the company’s journals, books, monographs and clinical information solutions as well as resources from other information providers and major health and government organizations. Also available is information typically used by practicing nurses and physicians, plus resources designed specifically for patients and their families. The site also links to other authoritative resources, including the WHO and the U.S. Centers for Disease Control and Prevention. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals’ advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ digitized journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com. Contact Details Elsevier Andrew Davis +44 7393 242466 andrew.davis@elsevier.com Elsevier Communications, US Dan DiPietro-James +1 773-251-8744 dan.james@elsevier.com Company Website https://www.elsevier.com/

August 15, 2022 04:00 AM Eastern Daylight Time

This Electric Toothbrush Has 6 Cleaning Modes For Reportedly Brighter Smiles

Bruush Oral Care Inc.

https://profiles.smallcapsdaily.com/bruush/ Toothbrushes have come a long way since Babylonians and Egyptians started brushing their teeth with frayed twigs around 3000 BCE. The first more modern toothbrush with a handle carved from cattle bone and a brush made from swine bristles was produced in England around 1780. Natural bristles were used until DuPont de Nemours Inc. (NYSE: DD) invented nylon, which started the development of the truly modern toothbrush in 1938 and the first electric toothbrush in 1939. Although electric toothbrushes date back more than 80 years, they have seemingly not achieved widespread adoption. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Electric toothbrushes clean teeth, gums and tongue by using rotation or side-by-side movement of the head. Electric toothbrushes are an effective way to remove plaque and reduce gingivitis, and studies show they are more thorough at cleaning teeth than traditional manual toothbrushes. But the moderate adoption rate of the devices arguably demonstrates that consumers need to be educated and provided compelling value propositions to buy them. Cost is a major constraint to the market, and people don’t see them as an attractive addition to their bathroom countertops. Better Brushing? Enter Brüush (NASDAQ: BRSH). While most electric toothbrushes provide 500 strokes per minute, Brüush says its model provides up to 31,000 strokes per minute, attacking plaque 100 times more vigorously than a manual toothbrush. Brüush has six cleaning modes for every type of brusher. The Brüush lithium-ion battery is built to last four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. The Brüush toothbrush, which comes in five colors with three brush heads and a USB power adapter and charger, retails for $79. And if you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — that’s just $6 per brush head. Replacing brush heads for Koninklijke Philips N.V.’s (NYSE: PHG) Sonicare can cost as much as $43 for a three-pack, and the price of Procter & Gamble Co. (NYSE: PG) Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. Brüush estimates that 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generation when it comes to shopping, possibly a positive for a company where its website accounts for the majority of sales. Visit Brüush’s website to learn more about the company and its products. About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR Colette Eymontt colette@tradigitalir.com Company Website https://www.bruush.com

August 11, 2022 01:41 PM Eastern Daylight Time

This Electric Toothbrush Has 6 Cleaning Modes For Reportedly Brighter Smiles

Benzinga

Toothbrushes have come a long way since Babylonians and Egyptians started brushing their teeth with frayed twigs around 3000 BCE. The first more modern toothbrush with a handle carved from cattle bone and a brush made from swine bristles was produced in England around 1780. Natural bristles were used until DuPont de Nemours Inc. (NYSE: DD) invented nylon, which started the development of the truly modern toothbrush in 1938 and the first electric toothbrush in 1939. Although electric toothbrushes date back more than 80 years, they have seemingly not achieved widespread adoption. The global electric toothbrush market size was estimated to be worth $4.3 billion in 2022 and projected to increase to just over $6 billion by 2027, according to Statista. Electric toothbrushes clean teeth, gums and tongue by using rotation or side-by-side movement of the head. Electric toothbrushes are an effective way to remove plaque and reduce gingivitis, and studies show they are more thorough at cleaning teeth than traditional manual toothbrushes. But the moderate adoption rate of the devices arguably demonstrates that consumers need to be educated and provided compelling value propositions to buy them. Cost is a major constraint to the market, and people don’t see them as an attractive addition to their bathroom countertops. Better Brushing? Enter Brüush (NASDAQ: BRSH). While most electric toothbrushes provide 500 strokes per minute, Brüush says its model provides up to 31,000 strokes per minute, attacking plaque 100 times more vigorously than a manual toothbrush. Brüush has six cleaning modes for every type of brusher. The Brüush lithium-ion battery is built to last four weeks on a single charge, and the compact magnetic case makes traveling with the device convenient. The Brüush toothbrush, which comes in five colors with three brush heads and a USB power adapter and charger, retails for $79. And if you sign up for a subscription, Brüush will send you three new brush heads every six months for $18 — that’s just $6 per brush head. Replacing brush heads for Koninklijke Philips N.V.’ s (NYSE: PHG) Sonicare can cost as much as $43 for a three-pack, and the price of Procter & Gamble Co. (NYSE: PG) Oral-B line of brush heads reaches as high as $40 for a three-pack, depending on the model. Brüush estimates that 70% of its customer base is between ages 18 and 45 years old, a group that’s under-penetrated compared to baby boomers in terms of using an electric toothbrush. This age group also consists of the first digital generation when it comes to shopping, possibly a positive for a company where its website accounts for the majority of sales. Visit Brüush’s website to learn more about the company and its products. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 11, 2022 09:52 AM Eastern Daylight Time

Ellie Diagnostics Expands its Laboratory Services to Louisville, Kentucky

Ellie Diagnostics

National flagship laboratory brings innovation to the veterinary industry Ellie Diagnostics, the leading independent diagnostics services provider for veterinarians, today announced the official grand opening of its newest laboratory in Louisville, Kentucky. This modern laboratory provides veterinary clinics across the country with a broad array of highly accurate diagnostic results just hours after patient samples are sent to the lab, and it will employ up to 100 veterinary professionals. Construction on this impressive 33,000 sq./ft. facility began in March 2022, and after an extremely fast development timeline, now enables Ellie Diagnostics to significantly expand its footprint across the United States. This innovative lab, located near the world’s largest UPS air hub in Louisville, will support all veterinarians with the best care, customized services, and flexibility to help grow their practice by identifying and treating diseases earlier than ever before. “Rapid growth in the veterinary industry and increasing demand for high quality, contract-free laboratory services prompted Ellie Diagnostics to open this large state-of-the-art laboratory,” said Founder and Chief Executive Officer Mark DeCourcy. “It is an immense pleasure to expand our operations to the great city of Louisville, and we would like to thank the government officials of Kentucky for their continued support through this process. Our gorgeous new lab is an amazing place to work for veterinary professionals and offers a wonderful environment for individuals looking to help pets on a larger scale.” Ellie Diagnostics ensures next day, early-morning patients’ diagnostic so veterinarians can quickly determine the underlying disease and begin treatment, thereby helping pets live longer, healthier lives. In addition, several tests come with an industry-leading Wellie Report that helps consumers understand their pets’ health and the importance of annual bloodwork for preventative care. About Ellie Diagnostics Ellie Diagnostics is the fastest growing independent veterinary diagnostics company in the United States, providing innovative services to veterinarians nationwide. Ellie provides next-day lab results, complimentary shipping, pathology consultations, data protection, mobile access to orders and results and innovative laboratory reporting. Their comprehensive test menu includes routine lab testing, histopathology, cytology, microbiology, and a wide variety of specialty tests. To learn more, visit www.elliediagnostics.com. Contact Details Ellie Diagnostics Jeff Gwynn, Vice President of Marketing +1 972-619-9969 jgwynn@elliediagnostics.com Company Website https://www.elliediagnostics.com/

August 11, 2022 09:30 AM Eastern Daylight Time

This Company Reports Moving Toward FDA Approval To Provide Pain-Free Diabetes Monitoring

Benzinga

Caused predominantly by genetic predisposition, immune disorders and other factors, such as unhealthy diet and exercise habits, diabetes is one of the most common lifelong chronic diseases in the world. According to the World Health Organization (WHO), there are nearly 450 million cases of diabetes worldwide, and the number in the U.S. could reach 40 million by 2030 and more than 60 million by 2060. Many believe the numbers could be more significant because large numbers of the population might be undiagnosed and at high risk. In recent years, with the rise of global diabetes expected to reach nearly 700 million by 2035, a growing number of patients are suffering from pain and infections caused by the invasive and frequent nature of using mainstream commercial glucose meters. The most common cutaneous complications are wear-related erythema, itching, and induration, but more severe cases, typically related to bacteria infection, continue to grow as well ( source 1 and 2 ). This has led to the need for noninvasive blood glucose monitoring technology, which could relieve numerous issues that many diabetes patients face. Noninvasive blood glucose monitoring refers to the detection of human blood glucose without causing damage to human tissues. Many noninvasive blood glucose detection methods can be divided into the optical, microwave and electrochemical processes. Medical imaging technologies are gaining global relevance in the medical community to assist clinicians in the diagnosis and guiding therapeutic treatment of patients. The big plus is that it's noninvasive and offers high-resolution results. The most common medical imaging technologies are computed tomography, magnetic resonance imaging and ultrasonography. Noninvasive imaging techniques are used in almost every medical field as a diagnostic tool and to monitor pathological progression or the efficacy of treatments. Several imaging tools are available to provide structural and functional information about tissue and organ physiology. New hybrid devices and multimodal imaging offer opportunities for research and use in clinics. Companies like General Electric Co. (NYSE: GE) Healthcare, Lantheus Holdings Inc. (NASDAQ: LNTH), Varex Imaging Corp. (NASDAQ: VREX) and OSI Systems Inc. (NASDAQ: OSIS) have invested heavily in medical imaging products, but most are better known for other medical offerings or other industries altogether. Know Labs Inc. (OTCQB: KNWN), an emerging developer in noninvasive medical diagnostics, focuses on developing its proprietary spectroscopic technologies using the electromagnetic spectrum. The goal is to accurately identify and measure a wide range of organic and inorganic materials, molecules and compositions of matter. Know Labs’ technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It refers to its technology as Bio-RFID™, which can be integrated into various wearable, mobile or bench-top devices. The company’s patented and patent-pending technology makes it possible to effectively identify and monitor analyses that could only previously be performed by invasive, expensive and time-consuming lab-based tests. The first application of its Bio-RFID technology will reportedly be in a product marketed as a noninvasive glucose monitor, giving the user real-time information on blood glucose levels. Know Labs’ leadership says it's confident it will be the first company to bring an FDA-cleared noninvasive glucose monitoring device to market. Know Labs is conducting a 200-person internal clinical trial of Bio-RFID, which will help the company refine its algorithm and demonstrate Bio-RFID’s accuracy in a large population.. Previous internal tests demonstrated Bio-RFID has an accuracy on par or better than currently available solutions, which is an important step towards FDA submission. For more information on Know Labs Inc., visit knowlabs.co. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

August 10, 2022 02:58 PM Eastern Daylight Time

Slashing Methane Emissions 30% By 2030 Could Be Key To Achieving Net Zero Targets — Here’s What AgTech Companies Are Doing To Help

Pond Technologies Holdings Inc.

The latest estimates put annual global methane emissions at 580 million tonnes (Mts) per year, creating atmospheric concentrations that are 2½ times denser than preindustrial levels. About 25% of that methane comes from the agricultural sector alone — mostly from gassy cows whose burps contain methane. With an estimated 1.4 billion cows worldwide and each cow belching approximately 220 pounds of methane each year, those burps add up. President Biden has even supported a bill that would tackle this issue, to the tune of $20 billion, due to its impact on the environment. That’s why companies like Pond Technologies Holdings Inc. ( OTCQB: PNDHF ) are exploring cost-effective, scalable ways to cut agricultural methane emissions and help nations around the world meet their Global Methane Pledge. Nations Need To Cut Methane Emissions If They Hope To Hit Net Zero Goals As part of the Global Methane Pledge launched at the 2021 United Nations Climate Change Conference (COP26) last year, 111 countries collectively responsible for 45% of methane emissions committed to reduce those emissions to 30% below 2020 levels by 2030. Methane is one of the most potent greenhouse gasses in Earth’s atmosphere — it has over 80 times the warming power of carbon dioxide and accounts for as much as 30% of the global temperature increase scientists expect to see in the next 20 years. Because of this enhanced warming effect, cutting 170 Mts, 30% of 2020 levels, in methane emissions would be the equivalent of scrubbing 4.7 billion to 6.1 billion tonnes of carbon dioxide emissions from the atmosphere per year. If the global temperature increase surpasses 1.5 C above its pre industrial average, scientists warn of the following changes in our climate could occur: Extreme heat events — like the recent record-breaking heat wave that swept Europe this summer, sparking wildfires in four countries and contributing to over 1,000 deaths — that used to happen once a decade or less would happen more than four times per decade. The risk of severe flooding will more than double for 73% of the world’s population. The total forest area at risk of forest fires would nearly double in the United States alone and fires could become about 37% more frequent. An average of more than 114 million people each month will be exposed to extreme drought conditions that could ruin food crops and make already-scarce drinking water even harder to come by. Curbing Agricultural Emissions Might Hinge On Discovering An Anti-Methane Diet For Livestock Methane in agriculture is produced primarily by livestock — especially cows — as their digestive process produces methane as a byproduct that is released when they burp. That means tackling methane levels for farmers means devising a way to make cows burp less. The approach that’s made the most progress is changing cows’ diet. Royal DSM (OTCQX: KDSKF), for example, has already shown some success with this approach using a feed additive called Bovaer that’s been shown to reduce methane from burping by around 30%. Algae May Hold Another Key To Slashing Methane Emissions In April, Pond Technologies partnered with Cross River Infrastructure Partners LLC and Livalta/AB Agri, a subsidiary of Associated British Foods plc (LSE: ABF) to identify algae strains that could reduce methane emissions when added to livestock feed. The research partnership could be a promising one as a separate study of red macroalgae (seaweed) found that it could cut methane emissions by up to 80% when added to cattle feed. However, scaling the production of seaweed would require turning large swaths of shorelines into seaweed farms, which could end up having its own environmental impacts on ocean and coastal ecosystems. That’s why Pond is partnering with these companies to explore microalgae strains that could offer the same methane-busting benefits as seaweed. Pond has already deployed what it reports is an innovative, scalable algae grow system that allows producers to grow microalgae in tanks where the conditions are optimized for algae growth. The tanks also help cut CO2 emissions themselves. Because algae use CO2 to grow, the proprietary Pond tanks can take the raw stack gas from power plants, factories and other high-emission facilities and convert it into clean, breathable air. The goal, then, is to identify microalgae strains that can be grown in these CO2-scrubbing platforms so that the companies can harvest them and turn them into feed additives. That way, each batch is pulling double duty: scrubbing emissions as it grows in the tank and curbing emissions again after it’s fed to livestock. Featured photo by Jan Koetsier on Pexels About Pond Technologies Located in Markham, Ontario, Pond has developed a proprietary system that can profitably transform CO2 into valuable products. Its Pond Carbon business focuses on absorbing greenhouse gas emissions, transforming these into food, feed, and nutraceutical ingredients. Pond recently added a Biotech division focused on the growth of unique strains of microalgae to be used as a reproductive medium for the expression of human antibodies and proteins. For more information, please visit https://www.pondtech.com/. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Pond Technologies, Inc. Grant Smith info@pondtech.com Benzinga Benzinga Brand Studio contributors@benzinga.com Company Website https://www.pondtech.com/

August 10, 2022 08:35 AM Eastern Daylight Time

Image

Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

NanoViricides, Inc.

https://profiles.smallcapsdaily.com/nnvc/ More than 30,000 confirmed or suspected cases of monkeypox have been reported across 93 countries in the world. While those numbers are still small scientists are now concerned that this sudden and unusual outbreak could lead to monkeypox becoming endemic in these large numbers of new countries where it was only seen sporadically before. With no specific treatment approved for the virus, doctors are turning to old smallpox medications — a disease that hasn’t had a reported case in nearly 50 years — and off-label use of an antiviral approved for smallpox that was developed as a medical countermeasure for potential bioterrorism, SIGA Technologies Inc. ’s (NASDAQ: SIGA) TPOXX. TPOXX has a number of shortcomings. Its injectable form requires each dosing to be infused over 6 hours, twice daily for several days. The injectable form may be considered rapid-acting, for severe cases, but cannot be given to patients with renal impairment (kidney damage). However, there is an oral capsule form. In terms of mechanism, TPOXX inhibits orderly exit of a mature virion. However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX. Most importantly, its utility in humans has not been established, as it was approved under the “Animal Rule” authority of the US FDA. It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection. Importantly, TPOXX, during its development, has been known to give rise to resistant viruses or escape mutants. Something that scientists fear can give rise to new monkeypox viruses that may be worse than the current ones, as has been happening with the SARS-CoV-2 virus of COVID-19. Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants. NanoViricides Inc. (NYSE American: NNVC ) reports that it may have a solution that would offer a more targeted treatment for the monkeypox virus that the virus may not escape from by mutations. The Strange And Sudden Outbreak Of Monkeypox What’s unusual about the outbreak is that although the “Patient Zero” in UK was connected to travel to Nigeria, and initial outbreaks occurred connected to raves in Europe, cases preceding to this outbreak have also been found to have occurred earlier, and not all the cases are linked to individuals who traveled to countries where the virus is usually found or have known contact with infected animals. While researchers are still trying to understand how that’s possible, the worry is that it’s been spreading silently and undetected for some time. And it can spread silently because an infected person is contagious even before the classic rash is present. The current outbreak also has different symptoms. Usually, a fever and swollen lymph nodes would precede the classic monkeypox rash and ulcers. However, with this virus, it appears that the rash can occur simultaneously with fever and swollen lymph nodes, or fever may even be absent. This is why possibly the rash of this virus was mistaken to be from other viruses such as herpes or shingles, although the monkeypox rashes behave distinctly differently from herpes or shingles rashes once formed. The Spread May Indicate Decreasing Immunity To Pox Viruses The monkeypox virus is a member of the poxviridae family along with smallpox, molluscum contagiosum and a few others. During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections. Since 1980, smallpox has been declared to be entirely eradicated worldwide with successful worldwide vaccination campaigns. Smallpox does not have any animal reservoirs, it infects only humans, which contributed to its elimination. Monkeypox outbreaks have been regular in the endemic regions of Western and Central Africa, with annually thousands of cases. Many of these cases are deemed to be tied to transmission from animals rather than human to human transmission. But the recent uptick outside these regions may be related to the fact that many people born after the smallpox programs of the 60s stopped in 1980 have never had the smallpox vaccine. Even in those who received the smallpox vaccine, it has been over forty to sixty years, and the vaccine was expected to be effective for fifteen to twenty years only. With the last natural reported case of smallpox occurring in 1977, smallpox vaccines were seen as no longer necessary and widespread vaccination campaigns disappeared. While smallpox hasn’t come back, that decline in vaccination rates slowly brewed a generation of people who could be more vulnerable to other pox viruses in the family. The NanoViricides Platform May Offer A Rapidly Deployable Solution NanoViricides is a developmental-stage company working on an antiviral platform that a virus theoretically can’t outsmart. By chemically attaching a binding ligand to a nano-sized polymer, the company has created an antiviral that can attach to a virus’s binding site, which doesn’t mutate even as a virus evolves and looks similar across most viruses. Once attached, the nanoviricide engulfs the viral cell, blocking it from reproducing or infecting healthy cells. The company states that the broad-spectrum antiviral can be tailored to a wide range of viruses with the goal of providing a treatment that remains effective against just about any species and strain of virus that threatens the human population. With clinical candidates for COVID-19 and Shingles having successfully completed the full battery of IND-enabling studies, and preclinical research underway for a pipeline of additional treatments tailored to Herpesviruses, HIV, and more, the company has already found ways to adapt the platform to a broad range of difficult to treat viral infections. The company hopes to tailor an antiviral based on this platform to the recent and worrying resurgence of monkeypox cases. The Company has recently announced in its press releases that it is about to begin testing on its drug candidates for monkeypox virus treatment. The Company also said that it is following a two-pronged strategy: (a) The first one being to develop a quick drug to deploy rapidly that improves upon the existing drug tecovirimat so that it can be used widely including in patients that TPOXX is contraindicated; and (b) The second one being continued development of highly effective drugs against poxviruses and other DNA viruses that can add a strong drug to the current one-drug repertoire of poxvirus treatments. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com TraDigital IR Colette Eymontt colette@tradigitalir.com Company Website http://www.nanoviricides.com

August 10, 2022 08:00 AM Eastern Daylight Time

Cortland Biomedical Announces Suite of Post-Processing Services and Technologies for Implantable Textiles

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full spectrum of global engineering, design and manufacturing capabilities, today announced that it has added a suite of post-processing services and technologies. Offered in conjunction with its extensive range of knitting, weaving, and braiding capabilities, the latest services will enable the company to provide its OEM customers with their implantable fabric or device in its final form. Cortland Biomedical is adept at working with customers to develop complex, customized textile structures with highly tailored mechanical properties. Its suite of post-processing capabilities now includes: Spin Finish Removal, which can improve the biocompatibility of implantable fibers in any textile construction. Edge Sealing, which is performed by using a variety of proprietary methods to apply heat and/or weld materials to minimize loose fibers and/or fraying without impacting the base material. Ultrasonic Welding, which can benefit implantable fabrics via the highly precise application of heat to create complex shapes via the attachments of components, etc. Heat Pressing, which provides the ability to further specialize and alter braided, woven, and knit textiles to stabilize and improve their performance. Shape Setting and Thermal Forming, which are processes that are employed to set a fabric into a specific and often complex geometry to suit a specific surgical application. Braid Tipping, which ensures that braided products are manufactured for optimal performance by stiffening the ends to reduce fraying. Laser cutting, which provides almost endless possibilities for the design and manufacturing of smaller components. “Our mission has always been to overcome the status quo when it comes to helping our customers develop innovative, sophisticated, customized textiles that may ultimately enable less invasive surgical procedures,” said Tara Yunkunis, business development manager, Cortland Biomedical. “Now, by offering this comprehensive suite of post-processing capabilities, we’ll be able to further help streamline product delivery and minimize the need for additional suppliers.” All services are performed at Cortland Biomedical’s state-of-the-art 35,000 sq. ft. manufacturing facility, which was strategically designed for purpose with input from medical device partners and seasoned textile engineers. Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

August 09, 2022 10:05 AM Eastern Daylight Time

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing treatments for ALS and diabetes, has been granted a patent from the United States Patent and Trademark Office for its cell therapy technology for treating ALS and other neurodegenerative diseases. This US patent joins additional patents granted to Kadimastem in the US, Israel and Europe for the treatment of ALS and for ALS drug screening. Kadimastem’s flagship product, AstroRx®, is a breakthrough technology that is comprised of a unique and large cell population of astrocytes derived from human pluripotent stem cells. The cells are intended to support the survival of neurons in the central nervous system (CNS, brain and spinal cord). These neurons are damaged by ALS, due to the malfunctioning of the patient’s own astrocytes. This situation hampers and annuls the neuromuscular signaling, which negatively affects muscle activity and leads to eventual paralysis and death. In December 2020, Kadimastem announced the results of the first of its kind, Phase I/IIa clinical trial, in which healthy and functioning astrocyte cells (AstroRx®) were injected into the spinal fluid of 10 ALS patients. Data showed that AstroRx® has the potential to slow the progression of ALS, as indicated by a clinical score called ALSFRS-R. Kadimastem plans to test repeated doses every three months of AstroRx® to achieve a continuous delay of the disease. Based on data that the company has to date, the company estimates that approximately 3 years after the completion of the upcoming clinical trial and receiving marketing approval, the potential size of the ALS market could reach approximately 0.5 billion dollars annually [1]. “The patent announced today strengthens our intellectual property portfolio in the field of ALS and other neurodegenerative diseases. Not only is it a good sign that the patent was granted in the United States in advance of the next trial, but the timing also gives AstroRx® a clear advantage as it increases the strategic value of the product,” said Kadimastem CEO Asaf Shiloni. “We are currently engaged in intensive activities to submit the IND by the end of 2022 as well as preparations for the start of a Phase IIa clinical study in 2023 in the United States.” Kadimastem Chief Scientist Professor Michel Revel said, “The ALS program is progressing well. The company’s broad patent portfolio was strengthened today, and we are on track to begin the much anticipated clinical trial of AstroRx® within months. I am excited to see our original vision come to fruition. The goal is to improve improve the treatment of ALS patients.” [1] https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/als/conditions/als_amyotrophic_lateral_sclerosis.html. https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/als/conditions/als_amyotrophic_lateral_sclerosis.html. Based on data from the aforementioned source (there are 30,000 ALS patients in the US, as well as 5,000 new cases of ALS that are diagnosed each year), and under the following assumptions: (1) gradual entry into the market after receiving approval for the product; (2) each cellular treatment in the US will cost the payer at least about 25,000 US dollars (based on the benchmark work performed by the company); (3) Each ALS patient in the US will require about 4 cellular treatments from the company in one year, that is, an annual cost of at least about 100,000 US dollars. The company’s assessments regarding the tests that will be performed as part of the clinical trial, regarding the size of the potential market activity for the company in the US, the completion of the clinical trial and the receipt of marketing approval, constitute forward-looking information, as defined in the Securities Law, 1968, which is based, among other things, on data that the company has as of the date of this report. It is clarified that such estimates may not materialize and/or materialize in a materially different manner from the above. About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company's lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS. IsletRx is the Company's second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Asaf Shiloni +972 73-797-1613 s.bazak@kadimastem.com Must Have Communications Marjie Hadad +1 917-790-1178 marjie@mhc-pr.com Company Website https://www.kadimastem.com/

August 09, 2022 07:00 AM Eastern Daylight Time

Image